FDC Roha facility successfully concludes USFDA audit
Mumbai: FDC has announced that the US Food and Drug Administration (USFDA) has successfully concluded the audit with no observations (Zero 483’s) at the company's Maharashtra manufacturing unit.
The inspection was conducted from 20th March 2023 to 24th March 2023.
Read also: Akums gets CDSCO panel nod to manufacture, market FDC Alfuzosin HCL, Tadalafil film coated tablets
Founded in 1936, FDC Limited is the pharmaceutical company headquartered in India. This facility is dedicated for Bulk APIs manufacturing. The Plant received the US-FDA approval 9 times in a row, since 1985. 90% of the APIs, manufactured at the Roha facility, are being exported to the USA, Canada, Japan, Malaysia, Europe and the Middle East countries
Read also: Morepen Labs Baddi facility clears USFDA inspection without any adverse observation
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.